All In Biotech

Drug Trial Radar · NCT03653832

Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial): A Randomised, Parallel-group, Allocation Concealed, Controlled, Open, Phase 3 Pragmatic Clinical and Cost- Effectiveness Trial With Internal Pilot

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,404

Actual

Start

Dec 11, 2018

Primary completion

Dec 14, 2023

Study completion Jul 31, 2024

Sponsor

Lead sponsor
University of EdinburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
West Hertfordshire Hospitals NHS Trust; Queen's University, Belfast; The University of Queensland; University Hospital of Wales; Edinburgh Napier University; King's College London; University of Warwick; University of Manchester; Royal Surrey County Hospital NHS Foundation Trust; University College, London; NHS Lothian; Imperial College London; University of Cambridge
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many patients in intensive care (ICU) need help to breathe on a breathing machine and need pain killers and sedatives to keep them comfortable and pain free. However, keeping patients too deeply sedated can make their ICU stay longer, can cause ICU confusion (delirium) and afterwards may cause distressing memories. Ideally patients should be kept less sedated, but it is difficult to get the balance of sedation and comfort right. The investigators want to know whether starting an alpha2-agonist drug early in ICU can help keep patients more lightly sedated but still comfortable, and whether patients spend less time on the ventilator. The investigators also want to know how safe they are and if they can improve important outcomes during ICU stay and during recovery. The investigators also want to know if they are value for money.

Conditions

  • Critical Illness

Interventions

  • DexmedetomidineDrug

    Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours. Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation.

  • ClonidineDrug

    Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours. Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation.

  • PropofolDrug

    Patients will continue to receive intravenous propofol according to current usual care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Successful Extubation Post-randomisation (Hours).Time frame: Ventilation status will be recorded twice daily from the date of randomisation until the date of documented successful extubation, or 180 days, whichever comes first.

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Belfast Health & Social Care Trust

    Belfast, United Kingdom

  • South Eastern Health and Social Trust

    Belfast, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Blackpool Teaching Hospitals NHS Foundation Trust

    Blackpool, United Kingdom

  • North Bristol NHS Trust

    Bristol, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Cardiff and Vale University Health Board

    Cardiff, United Kingdom

  • Countess of Chester Hospital NHS Foundation Trust

    Chester, United Kingdom

  • The Dudley Group NHS Foundation Trust

    Dudley, United Kingdom

  • NHS Dumfries and Galloway

    Dumfries, United Kingdom

  • NHS Lothian

    Edinburgh, United Kingdom

  • Medway NHS Foundation Trust

    Gillingham, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom

  • Harrogate and District NHS Trust

    Harrogate, United Kingdom

  • Wye Valley NHS Trust

    Hereford, United Kingdom

  • The Queen Elizabeth Hospital Kings Lynn NHS Foundation Trust

    Kings Lynn, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • University Hospitals of Leicester

    Leicester, United Kingdom

  • Lewisham and Greenwich NHS Trust

    Lewisham, United Kingdom

  • Aintree University Hospital Foundation Trust

    Liverpool, United Kingdom

  • Royal Liverpool and Broadgreen University Hospitals NHS Trust

    Liverpool, United Kingdom

  • Guys and St Thomas NHS Foundation Trust

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom

  • St George's University Hospitals NHS Foundation Trust

    London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Manchester University Foundation Trust

    Manchester, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle, United Kingdom

  • Aneurin Bevan University Health Board

    Newport, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust.

    Oxford, United Kingdom

  • Poole Hospitals NHS Foundation Trust

    Poole, United Kingdom

  • University Hospital Southampton NHSFT

    Southampton, United Kingdom

  • North Tees and Hartlepool NHS Foundation Trust

    Stockton-on-Tees, United Kingdom

  • Taunton and Somerset NHS Foundation Trust

    Taunton, United Kingdom

  • West Hertfordshire Hospitals NHS Trust

    Watford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.